Enos Bernasconi to HIV Infections
This is a "connection" page, showing publications Enos Bernasconi has written about HIV Infections.
Connection Strength
0.582
-
Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013-2017, in the Swiss HIV Cohort Study. Clin Infect Dis. 2020 07 27; 71(3):637-644.
Score: 0.034
-
Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. BMC Infect Dis. 2019 Oct 10; 19(1):834.
Score: 0.032
-
HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. J Acquir Immune Defic Syndr. 2019 08 15; 81(5):508-515.
Score: 0.032
-
Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study. Clin Infect Dis. 2019 02 15; 68(5):827-833.
Score: 0.031
-
Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. AIDS. 2018 11 28; 32(18):2759-2765.
Score: 0.031
-
Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Nature. 2018 09; 561(7723):406-410.
Score: 0.030
-
Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. Hematol Oncol. 2018 Dec; 36(5):757-764.
Score: 0.030
-
Is breastfeeding an equipoise option in effectively treated HIV-infected mothers in a high-income setting? Swiss Med Wkly. 2018; 148:w14648.
Score: 0.030
-
Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule. Clin Infect Dis. 2018 03 19; 66(7):1099-1108.
Score: 0.029
-
Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Mol Biol Evol. 2018 01 01; 35(1):27-37.
Score: 0.029
-
Adverse events of raltegravir and dolutegravir. AIDS. 2017 08 24; 31(13):1853-1858.
Score: 0.028
-
Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. Liver Int. 2018 03; 38(3):424-431.
Score: 0.028
-
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. BMC Infect Dis. 2017 07 06; 17(1):476.
Score: 0.028
-
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. Clin Infect Dis. 2017 05 01; 64(9):1275-1278.
Score: 0.027
-
Human papillomavirus antibody response following HAART initiation among MSM. AIDS. 2017 02 20; 31(4):561-569.
Score: 0.027
-
Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study. Clin Infect Dis. 2017 02 15; 64(4):490-497.
Score: 0.027
-
Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. Medicine (Baltimore). 2017 Jan; 96(2):e5849.
Score: 0.027
-
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterol. 2015 Jul 08; 15:79.
Score: 0.024
-
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010; 15(3):413-23.
Score: 0.016
-
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis. 2008 Apr 15; 46(8):1299-309.
Score: 0.015
-
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007; 12(8):1165-73.
Score: 0.013
-
Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. J Exp Med. 2018 06 04; 215(6):1589-1608.
Score: 0.007
-
High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study. AIDS Care. 2017 08; 29(8):1056-1061.
Score: 0.007